Injection Drug Use HIV Risk and Prevention HIV AIDS

Participation in any program of heroin or methadone substitution administered by a public organization was considered participation in an opioid maintenance program. Key populations at higher risk of HIV include people who sell sex, men who have sex with men, transgender people and people who inject drugs. People who inject drugs are at increased risk of HIV, tuberculosis (TB), and viral hepatitis B and C (HBV and HCV), in addition to overdose. Approximately 1 in 8 (or 1.4 million) of these people are living with HIV (UNODC World Drug Report, 2020), while 39.4% have viremic HCV infection (Grebely et al., Addiction, 2019). Harm reduction knowledge check scores showed modest yet significant improvement after respondents received the Six Moments training, although some knowledge gaps persisted; more data and trainings are needed to ensure the sustainability of the educational intervention.

Acute infections in intravenous drug users

The common assumption that providing the means for safer injection will encourage drug use and undermine drug treatment is contradicted by the data collected to date. The Amsterdam syringe exchange program has been collecting data longer than any other program; its results clearly show that syringe exchange has not encouraged drug use. As noted earlier, the program was begun in 1984, during which 25,000 sterile needles and syringes were distributed. The number distributed rose to 700,000 in 1987; it is estimated that 750,000 sterile needles and syringes will be distributed in 1988.

Access this article

Harm reduction knowledge and psychosocial vulnerabilities influence drug use and high-risk drug injection practices. Perceived likelihood of risk, severity, and susceptibility of SBI among PWID varies widely, and these beliefs can lead to risky injection practices in the context of withdrawal symptoms, drug injection network, and lived experiences. A repeated or temporary lapse in safe injection practices was a recurring theme, often in relation to the severity of addiction, feelings of hopelessness, and vulnerable social situation. Similarly, as reported by others, participants described putting on hold safe injection practices often when “sick” from opioid withdrawal [37]. Those challenging periods undermining PWID willingness to inject safely likely increased opportunities for bacterial introduction during the injection process.

Assistance for persons who use drugs

By Sara Hoffman, PharmDHoffman is a Kansas-based clinical pharmacist with experience working in hospitals, specialty clinics, and community pharmacies. While IVIG is widely considered a safe and effective treatment, not everyone is a candidate due to cost, logistical hindrances, or shortages of immunoglobulin availability. Many people are on IVIG indefinitely, but the good news is that most IVIG products only need to be infused around once every few weeks, so they should not take up too much of your time overall.

Access to hepatitis C testing and treatment for people who inject drugs and people in prisons — a global…

Participants reported a basic understanding of prevention of blood-borne viral transmission but limited understanding of SBI risk. Participants described engagement in high risk injection behaviors prior to hospitalization with SBI. These practices included polysubstance use, repetitive tissue damage, nonsterile drug diluting water and multipurpose use of water container, lack of hand and skin hygiene, re-use of injection equipment, network sharing, and structural factors leading to an unstable drug injection environment. Qualitative analysis led to the proposal of an Ecosocial understanding of SBI risk, detailing the multi-level interplay between individuals and their social and physical environments in producing risk for negative health outcomes. Infectious diseases are a major cause of morbidity and mortality among intravenous drug users (IVDU) [1-8]. Malnutrition, immunodeficiency, homelessness, and needle-sharing contribute to a high infection rate in these patients [7,9].

• Injection risk behaviors and participants’ perception of these risks with respect to SBI were highlighted during the interviews with resultant emergence of themes.
• This group of younger individuals is more likely to be rural, white, and female than prior high-burden populations.
• Understanding blood-borne viral transmission risk was also reinforced as a result of participants’ lived experiences, which subsequently would lead to avoidance of needle sharing practices.
• † Antibiotic prescribed for the longest period intravenously during one hospitalization.

IDU: infections, wounds, and other implications

• Therefore, the committee recommends that high priority be given to studies of the sexual and procreative behavior of IV drug users, including methods to reduce sexual and perinatal (mother-infant) transmission of HIV.
• Antibiotics are critical tools for preventing and treating infections caused by specific bacteria in people, animals and crops.
• Moreover, the knowledge base needed to design, implement, and evaluate measures to change high-risk behavior in IV drug users continues to grow.
• The drugs and diluents can increase tissue damage by potentially causing ischaemia, necrosis, vasospasm, and thrombosis.

Still, Hardy and coworkers (1987) have suggested that an additional 13 percent of deaths among IV drug users were related to HIV but did not meet the CDC criteria for AIDS. The number of non-AIDS deaths among IV drug users in New York City increased from 257 in 1978 to 1,607 in 1985 (Des Jarlais et al., 1988b). This increase is presumed to reflect fatal consequences of HIV infection that did not meet the iv drug use CDC surveillance definition for AIDS, including infections from nonopportunistic pathogens (see Table 3-4). Other factors, such as better record-keeping or better surveillance, can also result in increases in the number of reported deaths; however, one study of narcotic-related deaths in New York (Stoneburner et al., 1988) ruled out improved recognition and reporting in explaining increased mortality.

• It is critical to understand under what conditions IV drug users are more or less likely to disclose information and to remember past events accurately, particularly those events that may involve complex and variable patterns of behavior such as needle-sharing.
• The second generalization that can be made is that there is wide variation in the percentage of drug users that reported AIDS risk reduction in the different studies.
• Unfortunately, researchers simply are not yet proficient at measuring and conceptualizing that variation.
• Intravenous drug users often view the identifiers required in some research as an invasion of privacy and a means of uncovering issues and behaviors that they do not want uncovered.
• In the United States, there has been a similar complementarity between programs that provide the means for safer injection and drug treatment programs.

Psychosocial Interventions and Public Policies Related to Drug Injection Behavior and